• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/31/23 2:54:35 PM ET
    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    On Monday, 27 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • Esports Entertainment (NASDAQ:GMBL) was the smallest company by market cap to set a new 52-week low.
    • Theratechnologies (NASDAQ:THTX)'s stock came under the most pressure, trading down 252.48% to reach a new 52-week low.
    • Artesian Resources (NASDAQ:ARTNA) shares bounced back the most, actually rising 0.04% after hiting a new 52-week low.

    The following stocks set new 52-week lows on Monday:

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares moved down 18.14% on Monday to hit a new 52-week low of $25.48, drifting down 18.14%.
    • Impinj (NASDAQ:PI) shares hit a yearly low of $65.03. The stock was down 2.54% on the session.
    • Artesian Resources (NASDAQ:ARTNA) shares made a new 52-week low of $45.27 on Monday. The stock was down 0.04% for the day.
    • Vanda Pharma (NASDAQ:VNDA) shares hit a yearly low of $5.58. The stock was down 2.61% on the session.
    • Prelude Therapeutics (NASDAQ:PRLD) stock dropped to a yearly low on Monday of $3.92. Shares traded down 1.51%.
    • SWK Holdings (NASDAQ:SWKH) stock hit a yearly low of $15.87. The stock was up 0.38% for the day.
    • Silicom (NASDAQ:SILC) stock hit a yearly low of $29.00. The stock was down 25.43% for the day.
    • Complete Solaria (NASDAQ:CSLR) shares set a new 52-week low of $3.31. The stock traded down 7.95%.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock hit a new 52-week low of $0.32. The stock was down 8.33% on the session.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.51. The stock traded down 6.12%.
    • Dare Bioscience (NASDAQ:DARE) shares reached a new 52-week low of $0.73 on Monday morning, moving up 0.47%.
    • Delta Apparel (AMEX:DLA) shares set a new 52-week low of $8.36. The stock traded down 3.24%.
    • Theratechnologies (NASDAQ:THTX) shares set a new 52-week low of $1.74. The stock traded up 252.48%.
    • Purple Biotech (NASDAQ:PPBT) shares fell to $1.02 on Monday, setting a new 52-week low with a shift of down 4.5%.
    • Datasea (NASDAQ:DTSS) stock set a new 52-week low of $0.71 on Monday, moving down 3.97%.
    • Capstone Green Energy (NASDAQ:CGRN) shares set a new 52-week low of $0.92. The stock traded down 4.9%.
    • GRI Bio (NASDAQ:GRI) shares made a new 52-week low of $3.45 on Monday. The stock was up 2.59% for the day.
    • Pop Culture Gr (NASDAQ:CPOP) stock hit a new 52-week low of $0.39. The stock was down 3.15% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) shares reached a new 52-week low of $2.46 on Monday morning, moving down 5.58%.
    • Biolase (NASDAQ:BIOL) shares hit a yearly low of $5.75. The stock was down 10.07% on the session.
    • Takung Art (AMEX:TKAT) stock achieved a new 52-week low on Monday morning, hitting $0.16 and moving down 14.68%.
    • Bone Biologics (NASDAQ:BBLG) stock set a new 52-week low of $1.24 on Monday, moving down 2.27%.
    • Eightco Holdings (NASDAQ:OCTO) shares made a new 52-week low of $1.30 on Monday. The stock was down 4.14% for the day.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a yearly low of $0.85. The stock was down 13.73% for the day.
    • Esports Entertainment (NASDAQ:GMBL) shares set a new yearly low of $0.40 this morning. The stock was down 6.98% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $APLS
    $ARTNA
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    Impinj Inc.
    $PI
    11/7/2025$200.00Neutral
    UBS
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    Impinj Inc.
    $PI
    10/8/2025$200.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    9/26/2025$18.00Neutral → Sell
    Goldman
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Walsh Deina H

    4 - Bone Biologics Corp (0001419554) (Issuer)

    1/21/26 4:37:14 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Executive Officer Frelick Jeff

    4 - Bone Biologics Corp (0001419554) (Issuer)

    1/21/26 4:37:13 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Chief Medical Officer Baumal Caroline sold $37,250 worth of shares (1,882 units at $19.79), decreasing direct ownership by 2% to 89,324 units (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    1/21/26 4:19:30 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    SEC Filings

    View All

    GRI Bio Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - GRI Bio, Inc. (0001824293) (Filer)

    1/21/26 4:10:37 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Apellis Pharmaceuticals Inc.

    144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    1/20/26 3:10:40 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Apellis Pharmaceuticals Inc.

    144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    1/20/26 3:10:14 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Apellis Pharmaceuticals upgraded by BofA Securities with a new price target

    BofA Securities upgraded Apellis Pharmaceuticals from Neutral to Buy and set a new price target of $28.00

    1/21/26 8:25:13 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Impinj with a new price target

    UBS initiated coverage of Impinj with a rating of Neutral and set a new price target of $200.00

    11/7/25 8:30:20 AM ET
    $PI
    Industrial Machinery/Components
    Technology

    Wolfe Research initiated coverage on Apellis Pharmaceuticals

    Wolfe Research initiated coverage of Apellis Pharmaceuticals with a rating of Peer Perform

    11/6/25 8:48:03 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GRI Bio Announces Reverse Stock Split

    GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on January 15, 2026. The Reverse Split will legally take effect at 4:01 p.m. Easte

    1/21/26 4:01:00 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Datasea Pre-Announces Fiscal Year 2026 Second Quarter Results

    Gross Profit Increased 278% Year-over-Year with Significant Improvement in Gross Margin BEIJING, Jan. 21, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ:DTSS) ("Datasea" or the "Company"), a Nevada-based technology company specializing in acoustic high-tech solutions and 5G+AI multimodal digitalization, today pre-announced its unaudited financial results for the second quarter of fiscal year 2026, ended December 31, 2025. The financial highlights below are presented on a six-month basis for the period ended December 31, 2025. Fiscal Year 2026 Second Quarter Financial Highlights (Un

    1/21/26 9:30:00 AM ET
    $DTSS
    Computer Software: Prepackaged Software
    Technology

    SunPower Announces Record Financials in Q4'25

    OREM, Utah, Jan. 20, 2026 (GLOBE NEWSWIRE) -- SunPower Inc. (herein "SunPower," the "Company," or Nasdaq: "SPWR"), a solar technology, services, and installation company, will present its Q4'25 results via webcast today, Tuesday, January 20, at 1:00pm ET. Interested parties may access the webcast by registering here or by visiting the Events page within the IR section of the company website: https://investors.sunpower.com/news-events/events. Fellow Shareholders:The preliminary Q4'25 report is shown below compared to our Q3'25 SEC 10Q report. SPWR's Q4'25 and full-year 2025 SEC 10K report are scheduled to be filed by March 30, 2026. SunPower Q4'25 Revenue & Operating Income Statement1     

    1/20/26 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO O'Donnell Kevin J bought $250,000 worth of shares (171,233 units at $1.46) and was granted 400,000 shares, increasing direct ownership by 1,987% to 599,985 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/11/25 8:07:01 AM ET
    $OCTO

    Director Jennings Frank D bought $200,000 worth of shares (136,986 units at $1.46), increasing direct ownership by 796% to 154,189 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:59:46 PM ET
    $OCTO

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    SunPower Closes $37.5M Ambia Solar Acquisition

    OREM, Utah, Nov. 24, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (herein "SunPower," the "Company," or Nasdaq: "SPWR") a solar technology, services, and installation company, today announced that it has closed its $37.5 million strategic acquisition of Ambia Solar ("Ambia") to create the No. 5 U.S. residential solar company, based on Ohm Analytics rankings. SunPower CEO T.J. Rodgers said, "Due to our quick closing of the acquisition, we are raising our Q4'25 quarterly revenue estimate to $88 million. We still expect record operating income in Q4'25 and at least $2.0 million in operating income in Q1'26, the winter solar "down" quarter. In addition, and equally important, the acquisition brings

    11/24/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    SunPower Signs LOI to Acquire Ambia Solar

    OREM, Utah, Nov. 11, 2025 (GLOBE NEWSWIRE) -- SunPower (herein "SunPower," the "Company" or Nasdaq: "SPWR") – a solar technology, services, and installation company – today announced that it has agreed to acquire Ambia Solar ("Ambia"), based in Lindon, Utah, just 1.7 miles from SunPower's HQ. Ambia is the No. 19 U.S. solar company by installed megawatts as reported by Ohm Analytics. The companies have signed a non-binding LOI for $37.5 million in equity. The transaction will close this quarter (Q4'25), subject to customary closing conditions. (The verb "will" in this press release should be interpreted as "will pursue the result stated in a definitive agreement scheduled for Q4'25 and act

    11/11/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    SunPower Executes Major Sales Force Expansion Following Sunder Merger

    OREM, Utah, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (NASDAQ:SPWR) a solar technology, services, and installation company, this morning announced the successful integration of the Sunder salesforce into the company — as SunPower continues to execute on plan and expects to achieve record revenue of $83.3 million and record operating income of $3.5 million in Q4 2025. Eric Nielsen, SunPower's EVP of Sales said, "I am happy to report the integration of Sunder's salesforce into SunPower has been seamless and as a result, has enabled our team to continue to execute on plan without missing a beat. In addition, this deal has been well received across the industry — evidenced by the fact t

    10/30/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Impinj Announces Preliminary Fourth-Quarter 2025 Revenue and Adjusted EBITDA Ahead of Participation at 28th Annual Needham Growth Conference

    Impinj, Inc. (NASDAQ:PI), a leading RAIN RFID provider and Internet of Things pioneer, today announced that it expects fourth-quarter 2025 revenue near the high end of its prior guidance of $90.0 to $93.0 million and adjusted EBITDA above the midpoint of its prior guidance of $15.4 to $16.9 million. The company also announced that Chris Diorio, Impinj co-founder and CEO, and Cary Baker, Impinj CFO, will participate in a fireside chat at the 28th Annual Needham Growth Conference on Wednesday, January 14, 2026, at 11:45 a.m. ET / 8:45 a.m. PT. A live webcast and replay of the presentation will be available on the company's website at investor.impinj.com. Fourth-Quarter and Full-Year 2025

    1/13/26 4:15:00 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    SILICOM'S FOURTH QUARTER & FULL YEAR 2025 RESULTS RELEASE SCHEDULED FOR JANUARY 29, 2026

    - Conference Call Scheduled for Thursday, January 29, 2026 at 9:00am ET - KFAR SAVA, Israel, Jan. 5, 2026 /PRNewswire/ -- Silicom Ltd. (NASDAQ: SILC), an industry-leading provider of high-performance server/appliances networking solutions, announced today that it will be releasing its fourth quarter and full year 2025 results on Thursday, January 29, 2026. The Company will be hosting a conference call on that same day at 9:00am Eastern Time. On the call, management will review and discuss the results, and will also be available to answer investors' questions, following the prepared remarks. To participate, investors may either listen via a webcast link hosted on Silicom's website or via the

    1/5/26 8:30:00 AM ET
    $SILC
    Computer Communications Equipment
    Telecommunications

    Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and DARE to RECLAIM™ Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Ea

    11/13/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC